Cancer risk in patients with Parkinson's disease in South Korea: A nationwide, population-based cohort study

Joo Hyun Park, Do-Hoon Kim, Yong Gyu Park, Do-Young Kwon, Moonyoung Choi, Jin Hyung Jung, Kyungdo Han

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Introduction: The association between Parkinson's disease (PD) and cancer development is controversial, especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the overall cancer risk and risk for specific cancers in patients with PD in Korea. Methods: Using data from the Korean National Health Insurance Database, we analysed 52,009 patients diagnosed with PD between 2010 and 2015 and 260,045 individuals without PD. Patients previously diagnosed with cancer were excluded. The age- and sex-matched cohorts were followed up until 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the relationship between PD and cancer. Results: Patients with PD had a lower overall cancer risk (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.74–0.82) after adjustment for multiple covariates during 2,022,852.6 person-years of follow-up. Patients with PD showed significantly lower risk of laryngeal cancer (HR, 0.45; 95% CI, 0.21–0.84), gastric cancer (HR, 0.72; 95% CI, 0.63–0.82), colorectal cancer (HR, 0.675; 95% CI, 0.60–0.76), liver cancer (HR, 0.80; 95% CI, 0.67–0.95), pancreatic cancer (HR, 0.75; 95% CI, 0.62–0.91), lung cancer (HR, 0.73; 95% CI, 0.63–0.84), leukaemia (HR, 0.49; 95% CI, 0.24–0.89), uterine cervical cancer (HR, 0.64; 95% CI, 0.40–0.99) and prostate cancer (HR, 0.78; 95% CI, 0.66–0.91). Conclusion: This nationwide population-based cohort study revealed that patients with PD had lower overall cancer risk and lower risk of specific cancers. Contrary to the results of the recent Asian study, this large cohort study revealed that patients with PD were less likely to develop cancer than those without PD in Korea. Our results were consistent with those of previous Western studies, despite differences in ethnicity and environment.

Original languageEnglish
Pages (from-to)5-13
Number of pages9
JournalEuropean Journal of Cancer
Volume117
DOIs
Publication statusPublished - 2019 Aug 1

Fingerprint

Republic of Korea
Parkinson Disease
Cohort Studies
Confidence Intervals
Population
Neoplasms
Korea
Laryngeal Neoplasms
National Health Programs
Liver Neoplasms
Pancreatic Neoplasms
Proportional Hazards Models
Uterine Cervical Neoplasms
Stomach Neoplasms
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Leukemia
Odds Ratio
Databases

Keywords

  • Cancer
  • Epidemiology
  • Malignant tumour
  • Neoplasms
  • Neurodegenerative disease
  • Parkinson disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cancer risk in patients with Parkinson's disease in South Korea : A nationwide, population-based cohort study. / Park, Joo Hyun; Kim, Do-Hoon; Park, Yong Gyu; Kwon, Do-Young; Choi, Moonyoung; Jung, Jin Hyung; Han, Kyungdo.

In: European Journal of Cancer, Vol. 117, 01.08.2019, p. 5-13.

Research output: Contribution to journalArticle

Park, Joo Hyun ; Kim, Do-Hoon ; Park, Yong Gyu ; Kwon, Do-Young ; Choi, Moonyoung ; Jung, Jin Hyung ; Han, Kyungdo. / Cancer risk in patients with Parkinson's disease in South Korea : A nationwide, population-based cohort study. In: European Journal of Cancer. 2019 ; Vol. 117. pp. 5-13.
@article{93759f401f8c48d69e56b44a2f06b95b,
title = "Cancer risk in patients with Parkinson's disease in South Korea: A nationwide, population-based cohort study",
abstract = "Introduction: The association between Parkinson's disease (PD) and cancer development is controversial, especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the overall cancer risk and risk for specific cancers in patients with PD in Korea. Methods: Using data from the Korean National Health Insurance Database, we analysed 52,009 patients diagnosed with PD between 2010 and 2015 and 260,045 individuals without PD. Patients previously diagnosed with cancer were excluded. The age- and sex-matched cohorts were followed up until 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the relationship between PD and cancer. Results: Patients with PD had a lower overall cancer risk (hazard ratio [HR], 0.78; 95{\%} confidence interval [CI], 0.74–0.82) after adjustment for multiple covariates during 2,022,852.6 person-years of follow-up. Patients with PD showed significantly lower risk of laryngeal cancer (HR, 0.45; 95{\%} CI, 0.21–0.84), gastric cancer (HR, 0.72; 95{\%} CI, 0.63–0.82), colorectal cancer (HR, 0.675; 95{\%} CI, 0.60–0.76), liver cancer (HR, 0.80; 95{\%} CI, 0.67–0.95), pancreatic cancer (HR, 0.75; 95{\%} CI, 0.62–0.91), lung cancer (HR, 0.73; 95{\%} CI, 0.63–0.84), leukaemia (HR, 0.49; 95{\%} CI, 0.24–0.89), uterine cervical cancer (HR, 0.64; 95{\%} CI, 0.40–0.99) and prostate cancer (HR, 0.78; 95{\%} CI, 0.66–0.91). Conclusion: This nationwide population-based cohort study revealed that patients with PD had lower overall cancer risk and lower risk of specific cancers. Contrary to the results of the recent Asian study, this large cohort study revealed that patients with PD were less likely to develop cancer than those without PD in Korea. Our results were consistent with those of previous Western studies, despite differences in ethnicity and environment.",
keywords = "Cancer, Epidemiology, Malignant tumour, Neoplasms, Neurodegenerative disease, Parkinson disease",
author = "Park, {Joo Hyun} and Do-Hoon Kim and Park, {Yong Gyu} and Do-Young Kwon and Moonyoung Choi and Jung, {Jin Hyung} and Kyungdo Han",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.ejca.2019.04.033",
language = "English",
volume = "117",
pages = "5--13",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Cancer risk in patients with Parkinson's disease in South Korea

T2 - A nationwide, population-based cohort study

AU - Park, Joo Hyun

AU - Kim, Do-Hoon

AU - Park, Yong Gyu

AU - Kwon, Do-Young

AU - Choi, Moonyoung

AU - Jung, Jin Hyung

AU - Han, Kyungdo

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Introduction: The association between Parkinson's disease (PD) and cancer development is controversial, especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the overall cancer risk and risk for specific cancers in patients with PD in Korea. Methods: Using data from the Korean National Health Insurance Database, we analysed 52,009 patients diagnosed with PD between 2010 and 2015 and 260,045 individuals without PD. Patients previously diagnosed with cancer were excluded. The age- and sex-matched cohorts were followed up until 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the relationship between PD and cancer. Results: Patients with PD had a lower overall cancer risk (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.74–0.82) after adjustment for multiple covariates during 2,022,852.6 person-years of follow-up. Patients with PD showed significantly lower risk of laryngeal cancer (HR, 0.45; 95% CI, 0.21–0.84), gastric cancer (HR, 0.72; 95% CI, 0.63–0.82), colorectal cancer (HR, 0.675; 95% CI, 0.60–0.76), liver cancer (HR, 0.80; 95% CI, 0.67–0.95), pancreatic cancer (HR, 0.75; 95% CI, 0.62–0.91), lung cancer (HR, 0.73; 95% CI, 0.63–0.84), leukaemia (HR, 0.49; 95% CI, 0.24–0.89), uterine cervical cancer (HR, 0.64; 95% CI, 0.40–0.99) and prostate cancer (HR, 0.78; 95% CI, 0.66–0.91). Conclusion: This nationwide population-based cohort study revealed that patients with PD had lower overall cancer risk and lower risk of specific cancers. Contrary to the results of the recent Asian study, this large cohort study revealed that patients with PD were less likely to develop cancer than those without PD in Korea. Our results were consistent with those of previous Western studies, despite differences in ethnicity and environment.

AB - Introduction: The association between Parkinson's disease (PD) and cancer development is controversial, especially in Asia. Therefore, we conducted a nationwide population-based cohort study to assess the overall cancer risk and risk for specific cancers in patients with PD in Korea. Methods: Using data from the Korean National Health Insurance Database, we analysed 52,009 patients diagnosed with PD between 2010 and 2015 and 260,045 individuals without PD. Patients previously diagnosed with cancer were excluded. The age- and sex-matched cohorts were followed up until 2016 for cancer development. Cox proportional hazards regression models were used to evaluate the relationship between PD and cancer. Results: Patients with PD had a lower overall cancer risk (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.74–0.82) after adjustment for multiple covariates during 2,022,852.6 person-years of follow-up. Patients with PD showed significantly lower risk of laryngeal cancer (HR, 0.45; 95% CI, 0.21–0.84), gastric cancer (HR, 0.72; 95% CI, 0.63–0.82), colorectal cancer (HR, 0.675; 95% CI, 0.60–0.76), liver cancer (HR, 0.80; 95% CI, 0.67–0.95), pancreatic cancer (HR, 0.75; 95% CI, 0.62–0.91), lung cancer (HR, 0.73; 95% CI, 0.63–0.84), leukaemia (HR, 0.49; 95% CI, 0.24–0.89), uterine cervical cancer (HR, 0.64; 95% CI, 0.40–0.99) and prostate cancer (HR, 0.78; 95% CI, 0.66–0.91). Conclusion: This nationwide population-based cohort study revealed that patients with PD had lower overall cancer risk and lower risk of specific cancers. Contrary to the results of the recent Asian study, this large cohort study revealed that patients with PD were less likely to develop cancer than those without PD in Korea. Our results were consistent with those of previous Western studies, despite differences in ethnicity and environment.

KW - Cancer

KW - Epidemiology

KW - Malignant tumour

KW - Neoplasms

KW - Neurodegenerative disease

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=85067398568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067398568&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2019.04.033

DO - 10.1016/j.ejca.2019.04.033

M3 - Article

C2 - 31229950

AN - SCOPUS:85067398568

VL - 117

SP - 5

EP - 13

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -